Stoke Therapeutics, Inc. STOK Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -11.2%+266pp | -277.3%+1,030pp | -1,307%-466pp | -841.3%— | |
| Net margin | -3.7%+240pp | -243.4%+949pp | -1,192.3%-378pp | -814.8%— | |
| Returns | |||||
| Return on equity | -2.4%+43.4pp | -45.8%+15.0pp | -60.8%-10.6pp | -50.2%-16.1pp | |
| Return on invested capital | -10.9%— | —— | —— | -133.6%— | |
| Efficiency | |||||
| Asset turnover | 0.5×+0.4× | 0.1×+0.1× | 0×0.0× | 0.1×— | |
| Liquidity | |||||
| Current ratio | 5.3×-0.5× | 5.8×-1.2× | 7×-0.8× | 7.8×-5.6× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $5.95+40.4% | $4.24+16.9% | $3.63-23.7% | $4.75-19.8% | |
| Valuation | |||||
| Market capitalization | $1.81B+210% | $584.23M+147% | $236.48M-35.0% | $363.98M-58.8% | |
| Price / sales | 9.8×-6.2× | 16×-10.9× | 26.9×-2.4× | 29.3×— | |
| Price / book | 5.1×+2.6× | 2.6×+1.1× | 1.5×-0.5× | 2×-2.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Stoke Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Stoke Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
